GH Stock Overview
A precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Guardant Health, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$32.65 |
| 52 Week High | US$37.04 |
| 52 Week Low | US$15.81 |
| Beta | 1.11 |
| 11 Month Change | 59.19% |
| 3 Month Change | 22.10% |
| 1 Year Change | 34.97% |
| 33 Year Change | -69.46% |
| 5 Year Change | -57.96% |
| Change since IPO | 1.40% |
Recent News & Updates
Market Participants Recognise Guardant Health, Inc.'s (NASDAQ:GH) Revenues Pushing Shares 36% Higher
Nov 08
An Intrinsic Calculation For Guardant Health, Inc. (NASDAQ:GH) Suggests It's 44% Undervalued
Oct 25Recent updates
Market Participants Recognise Guardant Health, Inc.'s (NASDAQ:GH) Revenues Pushing Shares 36% Higher
Nov 08An Intrinsic Calculation For Guardant Health, Inc. (NASDAQ:GH) Suggests It's 44% Undervalued
Oct 25Is There Now An Opportunity In Guardant Health, Inc. (NASDAQ:GH)?
Sep 24Guardant Health: Top-Line Growth Undeniable, Compounding Ability Remains Unseen
Aug 21Guardant Health, Inc.'s (NASDAQ:GH) P/S Is Still On The Mark Following 26% Share Price Bounce
Jul 31Guardant Health, Inc. (NASDAQ:GH) Shares Could Be 49% Below Their Intrinsic Value Estimate
Jul 12Guardant: Double-Digit Sales Projections Come At A Cost
Jun 06Is Now The Time To Look At Buying Guardant Health, Inc. (NASDAQ:GH)?
Jun 04Investors Appear Satisfied With Guardant Health, Inc.'s (NASDAQ:GH) Prospects As Shares Rocket 31%
May 14Does Guardant Health (NASDAQ:GH) Have A Healthy Balance Sheet?
Mar 29With Guardant Health, Inc. (NASDAQ:GH) It Looks Like You'll Get What You Pay For
Jan 21Does Guardant Health (NASDAQ:GH) Have A Healthy Balance Sheet?
Nov 20Is There Now An Opportunity In Guardant Health, Inc. (NASDAQ:GH)?
Sep 26A Look At The Fair Value Of Guardant Health, Inc. (NASDAQ:GH)
Sep 05Is Guardant Health (NASDAQ:GH) A Risky Investment?
Aug 15A Look At The Intrinsic Value Of Guardant Health, Inc. (NASDAQ:GH)
May 28Does Guardant Health (NASDAQ:GH) Have A Healthy Balance Sheet?
Apr 05Is Guardant Health (NASDAQ:GH) Using Too Much Debt?
Dec 28Shareholder Returns
| GH | US Healthcare | US Market | |
|---|---|---|---|
| 7D | 12.2% | 1.6% | 2.2% |
| 1Y | 35.0% | 2.1% | 31.7% |
Return vs Industry: GH exceeded the US Healthcare industry which returned 2.1% over the past year.
Return vs Market: GH exceeded the US Market which returned 31.7% over the past year.
Price Volatility
| GH volatility | |
|---|---|
| GH Average Weekly Movement | 8.6% |
| Healthcare Industry Average Movement | 7.0% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: GH has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: GH's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 1,774 | Helmy Eltoukhy | guardanthealth.com |
Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection.
Guardant Health, Inc. Fundamentals Summary
| GH fundamental statistics | |
|---|---|
| Market cap | US$4.03b |
| Earnings (TTM) | -US$512.41m |
| Revenue (TTM) | US$692.26m |
5.8x
P/S Ratio-7.9x
P/E RatioIs GH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GH income statement (TTM) | |
|---|---|
| Revenue | US$692.26m |
| Cost of Revenue | US$274.72m |
| Gross Profit | US$417.53m |
| Other Expenses | US$929.94m |
| Earnings | -US$512.41m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -4.15 |
| Gross Margin | 60.31% |
| Net Profit Margin | -74.02% |
| Debt/Equity Ratio | -1,900.1% |
How did GH perform over the long term?
See historical performance and comparison